The lancet. Gastroenterology & hepatologyHumansColitisUlcerativeDouble-Blind MethodMale
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Kaichun Wu, Changqing Zheng, Qian Cao, Yijuan Ding, Xiang Gao, Jie Zhong, Cheng-Tang Chiu, Hu Zhang, Xin Wang, Bangmao Wang, Jie Liang, Xiaowei Liu, Yongjian Zhou, Baohong Xu, Tae-Oh Kim
Published: 202510.1016/S2468-1253(25)00198-0
Abstract
BACKGROUND: Etrasimod is an oral, once-daily sphingosine 1-phosphate (S1P) receptor modulator for the treatment of active ulcerative colitis. In the randomised, placebo-controlled, double-blind phase 3 ENLIGHT UC study, also known as the ES101002 stu…
Preview only. Read the full abstract at the source